ATRS Antares Pharma Inc.

3.14
+0.02  (+1%)
Previous Close 3.12
Open 3.13
Price To Book 12.56
Market Cap 512,013,540
Shares 163,061,637
Volume 566,440
Short Ratio
Av. Daily Volume 1,232,064

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved December 8, 2011.
Anturol
Overactive bladder
Approved Oct 14, 2013.
OTREXUP
Rheumatoid arthritis (RA)
Approval announced February 14, 2018.
Makena - auto injector
Reduce the risk of preterm birth in women with a singleton pregnancy
FDA Approval announced October 1, 2018.
XYOSTED (testosterone enanthate)
Testosterone deficiency

Latest News

  1. Edited Transcript of ATRS earnings conference call or presentation 6-Aug-19 12:30pm GMT
  2. Antares Pharma Inc (ATRS) Q2 2019 Earnings Call Transcript
  3. Loss-Making Antares Pharma, Inc. (NASDAQ:ATRS) Expected To Breakeven
  4. Antares Pharma Reports Second Quarter 2019 Operating and Financial Results
  5. Antares Pharma to Report Second Quarter 2019 Financial and Operating Results
  6. Antares Pharma Announces Amendment to Existing Loan and Security Agreement With Hercules Capital
  7. Here is What Hedge Funds Think About Antares Pharma Inc (ATRS)
  8. Antares Pharma to Present at the Raymond James 2019 Life Sciences and MedTech Conference
  9. Have Insiders Been Selling Antares Pharma, Inc. (NASDAQ:ATRS) Shares This Year?
  10. Antares Pharma to Present at the Jefferies 2019 Healthcare Conference
  11. Antares Pharma to Present at the B. Riley FBR Institutional Investor Conference
  12. Edited Transcript of ATRS earnings conference call or presentation 2-May-19 12:30pm GMT
  13. Investors Who Bought Antares Pharma (NASDAQ:ATRS) Shares Three Years Ago Are Now Up 265%
  14. Antares Pharma: 1Q Earnings Snapshot
  15. Antares Pharma Reports First Quarter 2019 Operating and Financial Results
  16. Antares Pharma to Report First Quarter 2019 Financial and Operating Results
  17. Why Antares Pharma, Inc.'s (NASDAQ:ATRS) CEO Pay Matters To You
  18. New Research: Key Drivers of Growth for Progress Software, Antares Pharma, National Vision, NMI, Waters, and Kelly Services — Factors of Influence, Major Initiatives and Sustained Production
  19. Antares Pharma Announces Receipt of Orphan Drug Designation for the Treatment of Ectopic Pregnancy With Methotrexate